



HAL
open science

Trypsin resistance of the major peanut allergen Ara h 6 and allergenicity of the digestion products are abolished after selective disruption of disulfide bonds

Stéphane Hazebrouck, Blanche Guillon, Marie-Francoise Drumare, Evelyne Paty, Jean-Michel J.-M. Wal, Hervé Bernard

► To cite this version:

Stéphane Hazebrouck, Blanche Guillon, Marie-Francoise Drumare, Evelyne Paty, Jean-Michel J.-M. Wal, et al.. Trypsin resistance of the major peanut allergen Ara h 6 and allergenicity of the digestion products are abolished after selective disruption of disulfide bonds. *Molecular Nutrition and Food Research*, 2012, 56 (4), pp.548 - 557. 10.1002/mnfr.201100614 . hal-02645154

HAL Id: hal-02645154

<https://hal.inrae.fr/hal-02645154v1>

Submitted on 15 Sep 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

Trypsin resistance of the major peanut allergen Ara h 6 and allergenicity of the digestion products are abolished after selective disruption of disulfide bonds.

Stéphane Hazebrouck^{1*}, Blanche Guillon^{1*}, Marie-Françoise Drumare¹, Evelyne Paty², Jean-Michel Wal¹ and Hervé Bernard¹

*** These authors contributed equally to this work**

¹ INRA, UR 496, Unité d'Immuno-Allergie Alimentaire, CEA-SPI, 91191 Gif-sur-Yvette, France

² Université Paris Descartes Assistance Publique des Hôpitaux de Paris, Hôpital Necker Enfants Malades, 75743 Paris cedex 15, France.

Correspondence : Hervé Bernard, PhD, Laboratoire d'Immuno-Allergie Alimentaire, INRA, iBiTec-S, SPI-Bât. 136, CEA de Saclay, 91191 Gif-sur-Yvette cedex, France. **E-mail:** herve.bernard-INRA@cea.fr. **Tel:** +33-1-69-08-79-98. **Fax:** +33-1-69-08-59-07.

This is the peer reviewed version of the following article: “Trypsin resistance of the major peanut allergen Ara h 6 and allergenicity of the digestion products are abolished after selective disruption of disulfide bonds.”, which has been published in final form at

Hazebrouck, S., Guillon, B., Drumare, M.-F., Paty, E., Wal, J.-M. and Bernard, H. (2012), Trypsin resistance of the major peanut allergen Ara h 6 and allergenicity of the digestion products are abolished after selective disruption of disulfide bonds. *Mol. Nutr. Food Res.*, 56: 548-557. <https://doi.org/10.1002/mnfr.201100614>

This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.

Trypsin resistance of the major peanut allergen Ara h 6 and allergenicity of the digestion products are abolished after selective disruption of disulfide bonds.

Stéphane Hazebrouck^{1*}, Blanche Guillon^{1*}, Marie-Françoise Drumare¹, Evelyne Paty², Jean-Michel Wal¹ and Hervé Bernard¹

*** These authors contributed equally to this work**

¹ INRA, UR 496, Unité d'Immuno-Allergie Alimentaire, CEA-SPI, 91191 Gif-sur-Yvette, France

² Université Paris Descartes Assistance Publique des Hôpitaux de Paris, Hôpital Necker Enfants Malades, 75743 Paris cedex 15, France.

Correspondence : Hervé Bernard, PhD, Laboratoire d'Immuno-Allergie Alimentaire, INRA, iBiTec-S, SPI-Bât. 136, CEA de Saclay, 91191 Gif-sur-Yvette cedex, France. **E-mail:** herve.bernard-INRA@cea.fr. **Tel:** +33-1-69-08-79-98. **Fax:** +33-1-69-08-59-07.

Abbreviations: **CD:** circular dichroism, **MS:** mass spectrometry, **r:** recombinant, **RBL:** Rat basophilic leukemia, **DB:** disulfide bridge, **red:** reduced and S-alkylated.

Keywords: 2S-albumin, allergenicity, disulfide bridges, peanut, trypsin resistance.

Abstract

Scope: 2S-albumins Ara h 2 and Ara h 6 are the most widely recognized and potent allergens for peanut-allergic patients. These allergens are particularly resistant to proteolysis and the digestion products generally retain significant allergenicity. Five disulfide bridges (DB) stabilize Ara h 6 overall structure and their influence on the trypsin resistance and on the allergenicity of the digestion products was investigated.

Methods and results: Progressive disruption of each DB was performed by site-directed mutagenesis. Successful refolding of Ara h 6 variants was confirmed by circular dichroism. Trypsin resistance, IgE-binding capacity and allergenic potency, as assessed by *in vitro* mediator release assay with sera from peanut-allergic patients, was not affected by the deletion of the C-terminal DB at Cys⁸⁴-Cys¹²⁴. Additional disruption of DB at Cys¹⁴-Cys⁷¹ or at Cys⁷³-Cys¹¹⁵ rendered Arg^{16/20} or Arg¹¹⁴ susceptible to trypsinolysis, respectively, but affected principally the IgE-binding capacity of Ara h 6. DB disruption at Cys²⁶-Cys⁵⁸ or at Cys⁵⁹-Cys¹⁰⁷ led to an extensive proteolytic degradation and a complete loss of allergenic potency of the digestion products.

Conclusion: Selective disruption of the DB stabilizing the protease-resistant core of Ara h 6 permitted to abolish the allergenicity of the trypsin-degradation products.

1 Introduction

Peanut allergy represents a major threat of severe IgE-mediated reactions for children and adults [1-3]. It generally persists through adulthood, thus affecting approximately 1% of the total population [4, 5]. Recent studies on oral immunotherapy using crude peanut extract (CPE) provided promising results. However, use of hypoallergenic variants of peanut allergens has been further proposed to perform specific immunotherapy without the risk to expose patients to serious side-effects after CPE administrations [6-11].

Among the eleven allergens so far identified in peanut, Ara h 2 and Ara h 6 have been recently described as the most frequently recognized allergens by IgE antibodies from peanut-allergic patients and as the most potent effectors, accounting for up to 90% of the allergenic potency in CPE [12-17]. Ara h 2 and Ara h 6 belong to the family of 2S-albumins, particularly present in legumes, tree nuts and seeds. These proteins of low molecular weight possess a core structure stabilized by a network of four conserved disulfides bridges (DB) [18]. During seed maturation, most of 2S-albumins are processed in two large and small subunits with a molecular weight of 8-10 and 3-5 kDa, respectively [18, 19]. However, processing of 2S-albumins in peanut appears to be rather ineffective. Indeed, while a small amount of processed Ara h 6 coexists with the full-length protein, Ara h 2 does not seem to be degraded by peanut proteases [16, 20]. Nevertheless, the “typical” pattern of processed 2S-albumin in two small and large subunits can be observed with native Ara h 2 or Ara h 6 after trypsin digestion [21, 22]. The domain located between the two subunits is thereby particularly susceptible to proteolytic attack, even when Ara h 2 and Ara h 6 are properly folded. Otherwise, the compact three-dimensional structure is preserved by the DB network that provides a great resistance not only toward trypsin but also toward pepsin thus allowing Ara h 2 and Ara h 6 to reach almost intact the gut immune system [14, 22, 23]. Indeed, even after

cleavage between the large and small subunits, the two fragments remain associated by two DB, thus forming a heterodimer as immunoreactive as the intact protein [16, 21].

The conformational structure of Ara h 2 and Ara h 6 plays a critical role in the allergenicity. The development of functional tests using fluid-phase IgE binding, thus preserving allergen conformation, revealed that DB disruption by complete reduction and S-alkylation of Ara h 2 and Ara h 6 alters drastically the IgE-binding capacity and the allergenic potency [16, 24-27]. The relative importance of conformational epitopes compared to sequential ones was also demonstrated [26]. However, while characterization of linear B-cell epitopes is exhaustively undertaken, the role of the conformational epitopes in 2S-albumin allergenicity still needs to be investigated [18, 28-30]. Moreover, the design of novel hypoallergenic variants, which is generally based on the disruption of B-cell sequential epitopes, could be improved by considering the conformational epitopes accounting for the allergenic properties of peanut allergens [31].

We previously reported the cloning and the expression of a recombinant (r) Ara h 6 protein that, after correct refolding, exhibited an immunoreactivity similar to that of the natural counterpart [32]. In the present work, the impact of Ara h 6 conformation and stability on trypsin resistance and allergenicity of the breakdown products was addressed by studying the relative contribution of each DB.

2 Materials and Methods

2.1 Allergic patients

Ten children were recruited at the Paediatric Allergy Clinic of Hopital Necker-Enfants Malades (Paris, France, Table 1). According to their medical history, symptoms involved skin, respiratory tract, gastrointestinal tract and cardiovascular system. Peanut allergy was

confirmed by positive open oral food challenge and by high concentrations of serum Ara h 6-specific IgE. Agreements were received from the parents to perform scientific investigations.

2.2 Reagents and Materials

Unless otherwise stated, all reagents were of analytical grade from Sigma (St Louis, MO, USA). Reduction and S-alkylation of Ara h 6 was performed as previously described in order to prepare denatured Ara h 6 (H6_{red}) [16]. Labelled Ara h 6 was prepared by covalent linkage of the native protein to the tetrameric form of acetylcholinesterase [33].

2.3 Site-directed mutagenesis

Recombinant Ara h 6 variants, with Cys-Ala substitutions leading to the disruption of the corresponding DB, were generated by using the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA). The plasmid pET9c-psc33 that contains the *ara h 6* gene [32], was used as template for PCR amplifications with Pfu polymerase in the presence of sense and antisense primers as listed in Table 2. After site-directed mutagenesis, the entire coding region of *ara h 6* was verified by DNA sequencing in order to confirm Cys-Ala substitutions.

2.4 Protein Expression, refolding and purification

Overnight cultures of recombinant *E. coli* BL21(DE3) were used to inoculate fresh medium at a dilution of 1:40. Cultures were grown at 37°C until the optical density at 600nm reached 0.5. The expression of the recombinant proteins was then induced by adding isopropylthio-β-D-galactoside (1 mM) for 5h. After centrifugation, bacterial pellets were stored at -20°C until extraction.

Frozen pellet corresponding to 100 mL of culture was resuspended in 10 mL of Tris buffer (0.1M, pH 8) containing different protease inhibitors (bacitracin 50µg/mL,

benzamidine 300 μ g/mL, leupeptin 20 μ g/mL, chymostatin 20 μ g/mL, pepstatinA 2.5 μ g/mL, AEBSF 60 μ g/mL). After sonication (60 sec) and centrifugation (10 min, 10,000g, 4°C), the pellet was resuspended in 10 mL of extraction buffer (Tris 0.1M, pH 8, guanidine-HCl 6M, DTT 5mM) in order to solubilize the inclusion bodies for 2h on a rotary mixer at room temperature. Suspensions were then centrifuged (10 min, 10,000g, 4°C). As recombinant proteins are produced without tag, the supernatant containing the whole protein content of solubilized inclusions bodies was immediately submitted to the refolding protocol as previously described [32]. The full-length refolded rAra h 6 was then purified using RP-HPLC. Purified fractions were analyzed by gel electrophoresis under reducing conditions and by mass spectrometry before being freeze-dried in order to confirm that rAra h 6 was not degraded by bacterial proteases. Recombinant protein was resuspended in potassium phosphate buffer (0.1M, pH 7.4) and total protein concentration was determined with the BCA protein assay (Pierce Biotechnology, Rockford, IL 61105, USA).

2.5 Trypsin digestion

Influence of DB disruptions on Ara h 6 stability was addressed by testing its resistance toward proteolysis. Although Ara h 6 is also resistant to pepsin action, we chose to perform trypsin digestion of the different mutants. Indeed the potential trypsin-cleavage sites are distributed almost evenly in Ara h 6 sequence, especially in the N-terminus part of the protein, and they are more numerous than the potential pepsin-cleavage sites, as estimated with ExPASy PeptideCutter tool [34]. Recombinant Ara h 6 variants were thus subjected to trypsin digestion (Promega, 18000 U per mg of enzyme) in Tris buffer (20 mM, pH 8). One mg of Ara h 6 was incubated with 50 μ g of trypsin at 37°C under agitation for 4 hours. The reaction was stopped by adding protease inhibitors and samples were stored at -20°C until further

characterization. Digestion pattern was visualized by gel electrophoresis using 3 μg of protein resuspended in Laemmli buffer with β -mercaptoethanol.

2.6 Circular Dichroism spectroscopy

Circular dichroism (CD) analysis of the recombinant proteins (0.1 mg/mL in potassium phosphate buffer (20 mM, pH 7.4)) was performed at 20°C on a JASCO-810 spectropolarimeter using 0.1 cm path length cells. The spectrum was recorded from 190 to 250 nm at a scanning speed of 100 nm/min with a 1 sec time constant, a 0.1 nm resolution and a 2 nm constant band pass. Three spectra were accumulated for each construct. The averaged spectrum was corrected by subtracting the baseline spectrum obtained under identical conditions with buffer alone. The results are expressed as mean residue ellipticity ($\text{deg}\cdot\text{cm}^2\cdot\text{dmol}^{-1}$).

2.7 Mass spectrometric characterization

Mass determination was carried out using a matrix-assisted laser desorption ionization-time-of-flight instrument (MALDI-TOF, Voyager DE RP apparatus, PE Biosystems, France). Mass spectrometry analysis was performed on samples resuspended in carbonate buffer (50 mM, pH 8.5) under reducing and non-reducing conditions. Reducing treatment was performed with β -mercaptoethanol (250 μM) at 95°C for 10 min. The different samples were then diluted in 0.2% TFA solution just before mass spectrometry analysis. Samples were mixed in a 1:1 ratio with a matrix solution of α -cyano-4-hydroxycinnamic acid or sinapinic acid. Analysis was performed in reflector or linear negative mode.

2.8 IgE-immunoreactivity analysis

The IgE-binding capacity of the different variants was assessed by evaluating their capacity to inhibit IgE binding of labelled Ara h 6 in a reverse enzyme allergeo-sorbent test (EAST inhibition), as previously described [35]. Results were expressed as B/B_0 where B_0 and B represented the amount of Ara h 6 linked to immobilised IgE antibodies in the absence or presence of a known concentration of recombinant Ara h 6 variants, respectively. The IgE reactivity of competitors was calculated with the concentration inhibiting 50% of the IgE binding to Ara h 6 (IC₅₀).

2.9 Mediator release assay

RBL SX -38 cells, rat mast cells expressing α , β and γ chains of the human high-affinity receptor Fc ϵ RI for IgE, were used to perform degranulation tests, as previously described [24]. Cells were passively sensitized with human IgE antibodies immunopurified from a pool of 40 different sera from peanut-allergic patients (see supplemental Table S1). Mediator release, induced by incubation with different concentrations of recombinant Ara h 6 variants, was determined by measuring the enzymatic activity of β -hexosaminidase. Results were expressed as percentage of the reference release after activation of the sensitised cells with anti-human IgE (LE27 clone; 100 ng/mL).

2.10 Statistical analysis

Data were analyzed using the non-parametric Wilcoxon matched pairs signed rank test. Statistical analyses were performed with GraphPad Prism 5.01 software and a $P < 0.05$ was considered significant (* $P < 0.05$, ** $P < 0.01$ and *** $P < 0.001$).

3 RESULTS

3.1 Cloning and expression of Ara h 6 variants

As Ara h 6 possesses an additional DB (DB5) compared to the four canonical cystines in 2S-albumins (Figure 1), the mutational approach was initiated by removing DB5 at Cys⁸⁴-Cys¹²⁴, thus leading to the variant H6-5 (Table 2). The other four DB were then additionally removed in the corresponding variants H6-5.1, H6-5.2, H6-5.3 and H6-5.4. Finally, three different DB were removed in the variants H6-5.1.4 and H6-5.2.3. For these constructs, in addition to DB5, the disrupted DB were selected in regard to the structural proximity of Cys⁵⁸ and Cys⁵⁹ engaged in DB2 and DB3, and Cys⁷¹ and Cys⁷³ engaged in DB1 and DB4, respectively (Figure 1).

Regarding the expression level of the recombinant proteins and their purification, no significant differences were observed between the different variants (data not shown). As observed on SDS-PAGE analysis (Figure 2), the Ara h 6 variants were purified to near homogeneity. The average yield of recombinant allergen after refolding and purification was around 1 mg/L of culture.

3.2 Refolding of Ara h 6 variants

Spectroscopic analysis of secondary structure of the different Ara h 6 variants was performed using CD spectroscopy. The far UV spectra of most variants displayed a profile similar to that observed with rAra h 6 (Figure 3). In this case, spectra revealed a maximum at around 192 nm, a minimum at 208 nm and a shoulder near 222 nm. These spectra, characteristic of 2S-albumins, underlined the predominance of helical structures in Ara h 6. Only variant H6-5.2.3 and the reduced and S-alkylated Ara h 6 (H6_{red}) exhibited a CD spectrum characteristic of a random coiled nature.

3.3 Role of the disulfide bridges on the resistance of Ara h 6 to trypsin hydrolysis

Trypsinolysis of rAra h 6 led to the disappearance of the initial band at 14 kDa. The "typical" pattern of naturally processed 2S albumins was then observed with two large and small subunits of 10 kDa and 5 kDa, respectively. Identification of the tryptic products by MALDI-TOF MS localized the cleavage sites at Arg⁵-Gly⁶, Arg⁷-Gln⁸, Arg⁴⁷-Ser⁴⁸ and Arg⁵⁰-Ser⁵¹ (Figure 1 and Table 3). Under non-reducing conditions, the small (f6/8-47) and large (f51-124) subunits of rAra h 6 remained associated by two disulfide bonds, DB1 and DB2 (Figure 1), as confirmed by MS with an apparent mass of 13,787 Da (Table 3).

The removal of DB5 did not affect the degradation pattern of Ara h 6 as confirmed by MS analysis. In contrast, the additional deletion of DB2 or DB3 reduced drastically trypsin resistance of H6-5.2 and H6-5.3, as evidenced by the absence of heterodimeric structure (Figure 2). In fact, most of the potential cleavage sites were processed by trypsin and among the numerous fragments detected by MS, the largest one (f58-86/90) exhibited a mass of 3.9 kDa. The deletion of DB1 or DB4 was less detrimental for Ara h 6 resistance since heterodimeric structures were still detected after trypsinolysis. Disruption of DB1 exposed peptide bonds Arg¹⁶-Gln¹⁷ and Arg²⁰-Val²¹ to trypsin attack and resulted in an heterodimer containing a truncated small subunit f(17/21-47). Furthermore, the heterodimer persisting after trypsinolysis of H6-5.4 exhibited a truncated large subunit f(51-114) resulting from the cleavage after Arg¹¹⁴ (Figure 1). Disruption of three DB induced the complete degradation of H6-5.1.4 (Figure 2) and H6-5.2.3 (data not shown). Accordingly, reduction of the five DB led to a similar extensive degradation of H6_{red} by trypsin (data not shown).

3.4 Role of the disulfide bridges on IgE-binding capacity of Ara h 6

rAra h 6 and the variants H6-5, H6-5.1, H6-5.2 and H6-5.3 displayed similar capacity to inhibit the binding of IgE antibodies from patient #443 to Ara h 6 (Figure 4A). In contrast, IgE reactivity was substantially decreased for H6-5.4 and drastically reduced for H6-5.1.4,

H6-5.2.3 and H6_{red}, as revealed by much higher IC₅₀. Influence of DB4 disruption on IgE reactivity was confirmed by testing sera from nine other patients (Figure 5A). While IgE-binding capacity of Ara h 6 remained not affected by DB5 disruption, it was significantly decreased after the additional deletion of DB4, but also of DB1. Accordingly, IgE reactivity of H6-5.1.4 was further reduced but not totally abolished after the simultaneous disruption of DB1 and DB4. While deletion of either DB2 or DB3 did not affect significantly the IgE-binding capacity, simultaneous disruption of DB2 and DB3 led to a drastic loss of IgE reactivity.

Considering serum from patient #443, tryptic fragments from rAra h 6 and H6.5 displayed an inhibition capacity similar to that found before trypsinolysis (Figure 4B). After analysis of ten patients' sera, digestion of rAra h 6 and H6-5 appeared to induce a slight reduction of their IgE-binding capacity, with IC₅₀ only 2 to 3-fold higher than those determined for undigested variants (Figure 5A and 5B).

Compared to rAra h 6 tryptic fragments, the digestion products of H6-5.1 displayed a ten-fold reduced IgE reactivity (Figure 5B). Digestion of H6-5.4 resulted in a more substantial decrease but the digestion products retained a significant IgE reactivity with half of the tested sera (Figure 5B). No IgE-binding capacity was detected with tryptic fragments from other variants.

3.5 Role of the disulfide bridges on Ara h 6 capacity to trigger RBL SX-38 degranulation

The allergenic potencies of Ara h 6 variants missing one or two DB were comparable (Figure 6A). A substantial decrease in the maximal release was observed only with the variant H6-5.1.4 while H6-5.2.3 or H6_{red} were not able to induce significant RBL SX-38 degranulation.

Even after trypsinolysis, rAra h 6 and H6-5 remained potent elicitors of RBL SX-38 degranulation (Figure 6B). In fact, tryptic fragments of rAra h 6 or H6-5 were as efficient as

the undigested proteins. The tryptic fragments of H6-5.1 and H6-5.4 were also able to trigger *in vitro* degranulation although the concentration of digestion products required for inducing the maximal release was approximately 10-fold higher than that measured for rAra h 6. On the other hand, trypsin digestion of H6-5.2, H6-5.3 and H6-5.1.4 totally abrogated their capacity to induce RBL SX-38 degranulation.

4 Discussion

In certain allergens displaying conformational IgE epitopes, the disruption of intramolecular DB has been shown to induce protein unfolding and decrease of the allergenicity [31, 36-38]. Reduction and S-alkylation of 2S-albumins further demonstrated the importance of the DB network on the susceptibility to proteolytic digestion and on the persistence of large digestion products even after prolonged hydrolysis [22]. Moreover, reduced and S-alkylated Ara h 2 is unable to trigger effector cell degranulation [26]. Accordingly, in this work, reduced Ara h 6 could not induce RBL SX-38 degranulation or exhibit any IgE-binding capacity. The role of each DB on Ara h 6 susceptibility to trypsinolysis and on the allergenic potency of tryptic fragments was therefore investigated.

The non-canonical DB5 at Cys⁸⁴-Cys¹²⁴ was first removed. Although DB5 links the C-terminus of Ara h 6 to the compact fold, its disruption did not affect trypsin resistance or IgE reactivity, thus confirming that DB5 does not contribute to protein stability as no regular secondary structure is associated with the Asn¹⁰⁸-Cys¹²⁴ domain .

Deletion of DB1 (Cys¹⁴-Cys⁷¹) rendered only two additional peptidic bonds, Arg¹⁶-Gln¹⁷ and Arg²⁰-Val²¹, susceptible to trypsin attack. Interestingly, the domain between Gln⁸ and Gln¹⁷ corresponds to an immunodominant IgE-binding epitope in Ara h 2 [26, 30, 39]. Linear IgE-binding epitopes in Ara h 6 are not yet described. However, considering the similar context of exposure of these domains on the surface of Ara h 2 and Ara h 6 (Figure 1

and [26]), the domain Gln⁸-Gln¹⁷ could be an IgE-binding epitope in Ara h 6 as well. The reduced IgE-reactivity of H6-5.1 may thus result from the substitution of Cys¹⁴ by Ala in this putative epitope. However, as sequential epitopes require also an appropriate structural context for proper interactions with IgE antibodies [26], the modified exposure of domain Gln⁸-Gln¹⁷, which leads to the cleavage at Arg¹⁶ and Arg²⁰, may also impair its recognition by IgE antibodies. Accordingly, trypsin cleavage of the N-terminal part of the small subunit at Arg^{16/20} led to a further decrease of IgE reactivity, thus correlating with the presence of an immunodominant IgE-binding epitope. In the same way, disruption of DB4 (Cys⁷³-Cys¹¹⁵) permitted the cleavage after Arg¹¹⁴ and led to a substantial decrease of IgE reactivity. Here also, Cys¹¹⁵ may be involved in a putative IgE-binding domain between Gln¹¹³ and Glu¹¹⁸, as reported in Ara h 2 [30]. In addition, DB4 connects α 4 and α 5 helices that flank the “hypervariable region” between Gln⁸³ and Gln⁹¹, which is an immunodominant IgE-binding epitope of numerous 2S albumins [18]. Disruption of DB4 could thus disturb the correct exposure of epitopes located in the hypervariable region and in the C-terminal domain. Finally, when DB1 and DB4 were simultaneously removed, the IgE reactivity was further decreased. The heterodimer was no more observed after trypsinolysis, thus revealing that DB1 and DB4 somewhat contribute to the protease-resistance core of Ara h 6. However, despite the disruption of three DB out of five, CD analysis of H6-5.1.4 did not reveal drastic destabilization of the secondary structures, thus suggesting that the remaining DB2 and DB3 play predominant roles in the maintenance of the global fold of Ara h 6.

This was further confirmed with H6-5.2 and H6-5.3 variants. Indeed, disruption of DB2 or DB3 dramatically decreased trypsin resistance of Ara h 6. In particular, the peptidic bond Arg⁵⁷-Cys⁵⁸ on α -helix α 3 became susceptible to trypsin attack. Simultaneous deletion of both DB2 and DB3 also precluded the correct refolding of Ara h 6. DB2 and DB3 thus seem to play pivotal roles in the structural integrity of the hydrophobic core, which has been

described to involve the α -helices α_2 , α_4 and α_5 [21]. As DB2 and DB3 connect α_3 to α_2 and α_5 respectively (Figure 1), α_3 seems to be involved as well in the stabilization of Ara h 6 core. Surprisingly, IgE reactivity was not affected by the removal of DB2 or DB3, thus suggesting that the structural constraints imposed by DB2 and DB3 do not interfere with the exposure of immunodominant IgE epitopes and that Cys²⁶, Cys⁵⁸, Cys⁵⁹ and Cys¹⁰⁷ are not critical residues for IgE-binding.

Despite the reduced IgE reactivity of H6-5.1 and H6-5.4, the disruption of one or two DB did not affect the allergenic potency of Ara h 6. Even after the disruption of three DB, the variant H6-5.1.4 still displayed substantial allergenic potency. Such discrepancies between IgE-binding capacity and allergenic potency were also observed when comparing digested and undigested Ara h 6, or Ara h 2 [21]. In fact, the capacity to trigger RBL cell degranulation correlated with the presence of the heterodimeric structure in the digestion products, as observed with H6-5.1 and H6-5.4 digesta. Accordingly, digestion products of H6-5.2 and H6-5.3, with fragments smaller than 4 kDa, did not exhibit any allergenic potency thus confirming that the efficient cross-linking between receptor-bound IgE antibodies required a relatively preserved Ara h 6 core.

In conclusion, our results provide a better understanding of the role of each DB on the conformation of Ara h 6, on its resistance to trypsin and on its allergenicity. It would be now of great interest to extend this approach to other 2S-albumins, and, particularly to Ara h 2. The cross-reactivity between the two allergens could then be further investigated in order to identify common epitopes and determine the relative importance of sequential epitopes compared to conformational ones. In parallel with the mutagenesis of residues critical for the recognition of sequential epitopes by IgE antibodies, the targeted disruption of DB could be of great interest for the design of hypoallergenic variants, not only for specific immunotherapy

applications but also for the generation of hypoallergenic seeds containing 2S-albumins partially destabilized with only one or two DB disruptions and consequently more digestible.

The authors have declared no conflict of interest.

5 References

- [1] Burks, A. W., Peanut allergy. *Lancet* 2008, *371*, 1538-1546.
- [2] Bock, S. A., Muñoz-Furlong, A., Sampson, H. A., Further fatalities caused by anaphylactic reactions to food, 2001-2006. *J Allergy Clin Immunol* 2007, *119*, 1016-1018.
- [3] Pumphrey, R. S., Gowland, M. H., Further fatal allergic reactions to food in the United Kingdom, 1999-2006. *J Allergy Clin Immunol* 2007, *119*, 1018-1019.
- [4] Rona, R. J., Keil, T., Summers, C., Gislason, D., *et al.*, The prevalence of food allergy: a meta-analysis. *J Allergy Clin Immunol*. 2007, *120*, 638-646.
- [5] Sicherer, S. H., Munoz-Furlong, A., Godbold, J. H., Sampson, H. A., US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. *J Allergy Clin Immunol*. 2010, *125*, 1322-1326.
- [6] Hofmann, A. M., Scurlock, A. M., Jones, S. M., Palmer, K. P., *et al.*, Safety of a peanut oral immunotherapy protocol in children with peanut allergy. *J Allergy Clin Immunol*. 2009, *124*, 286-291, 291.
- [7] Jones, S. M., Pons, L., Roberts, J. L., Scurlock, A. M., *et al.*, Clinical efficacy and immune regulation with peanut oral immunotherapy. *J Allergy Clin Immunol*. 2009, *124*, 292-300, 300.
- [8] Thyagarajan, A., Varshney, P., Jones, S. M., Sicherer, S., *et al.*, Peanut oral immunotherapy is not ready for clinical use. *J Allergy Clin Immunol* 2010, *126*, 31-32.
- [9] Varshney, P., Steele, P. H., Vickery, B. P., Bird, J. A., *et al.*, Adverse reactions during peanut oral immunotherapy home dosing. *J Allergy Clin Immunol* 2009, *124*, 1351-1352.
- [10] Ferreira, F., Ebner, C., Kramer, B., Casari, G., *et al.*, Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. *FASEB J* 1998, *12*, 231-242.

- [11] King, N., Helm, R., Stanley, J. S., Vieths, S., *et al.*, Allergenic characteristics of a modified peanut allergen. *Mol Nutr Food Res.* 2005, *49*, 963-971.
- [12] Burks, A. W., Williams, L. W., Connaughton, C., Cockrell, G., *et al.*, Identification and characterization of a second major peanut allergen, Ara h II, with use of the sera of patients with atopic dermatitis and positive peanut challenge. *J Allergy Clin Immunol* 1992, *90*, 962-969.
- [13] Chatel, J. M., Bernard, H., Orson, F. M., Isolation and characterization of two complete Ara h 2 isoforms cDNA. *Int Arch Allergy Immunol* 2003, *131*, 14-18.
- [14] Suhr, M., Wicklein, D., Lepp, U., Becker, W. M., Isolation and characterization of natural Ara h 6: evidence for a further peanut allergen with putative clinical relevance based on resistance to pepsin digestion and heat. *Mol Nutr Food Res.* 2004, *48*, 390-399.
- [15] Koppelman, S. J., de Jong, G. A., Laaper-Ertmann, M., Peeters, K. A., *et al.*, Purification and immunoglobulin E-binding properties of peanut allergen Ara h 6: evidence for cross-reactivity with Ara h 2. *Clin Exp Allergy.* 2005, *35*, 490-497.
- [16] Bernard, H., Mondoulet, L., Drumare, M. F., Paty, E., *et al.*, Identification of a new natural Ara h 6 isoform and of its proteolytic product as major allergens in peanut. *J Agric.Food Chem.* 2007, *55*, 9663-9669.
- [17] Flinterman, A. E., van, H. E., den Hartog Jager, C. F., Koppelman, S., *et al.*, Children with peanut allergy recognize predominantly Ara h2 and Ara h6, which remains stable over time. *Clin Exp Allergy.* 2007, *37*, 1221-1228.
- [18] Moreno, F. J., Clemente, A., 2S Albumin Storage Proteins: What Makes them Food Allergens? *Open.Biochem J.* 2008, *2*:16-28.
- [19] Shewry, P. R., Napier, J. A., Tatham, A. S., Seed storage proteins: structures and biosynthesis. *Plant Cell.* 1995, *7*, 945-956.

- [20] Marsh, J., Rigby, N., Wellner, K., Reese, G., *et al.*, Purification and characterisation of a panel of peanut allergens suitable for use in allergy diagnosis. *Mol Nutr Food Res* 2008, *52 Suppl 2*, S272-285.
- [21] Lehmann, K., Schweimer, K., Reese, G., Randow, S., *et al.*, Structure and stability of 2S albumin-type peanut allergens: implications for the severity of peanut allergic reactions. *Biochem J.* 2006, *395*, 463-472.
- [22] Koppelman, S. J., Hefle, S. L., Taylor, S. L., de Jong, G. A., Digestion of peanut allergens Ara h 1, Ara h 2, Ara h 3, and Ara h 6: a comparative in vitro study and partial characterization of digestion-resistant peptides. *Mol Nutr Food Res.* 2010, *54*, 1711-1721.
- [23] Sen, M., Kopper, R., Pons, L., Abraham, E. C., *et al.*, Protein structure plays a critical role in peanut allergen stability and may determine immunodominant IgE-binding epitopes. *J Immunol.* 2002, *169*, 882-887.
- [24] Blanc, F., del-Patient, K., Drumare, M. F., Paty, E., *et al.*, Capacity of purified peanut allergens to induce degranulation in a functional in vitro assay: Ara h 2 and Ara h 6 are the most efficient elicitors. *Clin Exp Allergy.* 2009, *39*, 1277-1285.
- [25] Palmer, G. W., Dibbern, D. A., Jr., Burks, A. W., Bannon, G. A., *et al.*, Comparative potency of Ara h 1 and Ara h 2 in immunochemical and functional assays of allergenicity. *Clin Immunol.* 2005, *115*, 302-312.
- [26] Albrecht, M., Kuhne, Y., Ballmer-Weber, B. K., Becker, W. M., *et al.*, Relevance of IgE binding to short peptides for the allergenic activity of food allergens. *J Allergy Clin Immunol.* 2009, *124*, 328-336, 336.
- [27] Porterfield, H. S., Murray, K. S., Schlichting, D. G., Chen, X., *et al.*, Effector activity of peanut allergens: a critical role for Ara h 2, Ara h 6, and their variants. *Clin Exp Allergy.* 2009, *39*, 1099-1108.

- [28] Pomes, A., Relevant B cell epitopes in allergic disease. *Int Arch Allergy Immunol.* 2010, *152*, 1-11.
- [29] Shreffler, W. G., Lencer, D. A., Bardina, L., Sampson, H. A., IgE and IgG4 epitope mapping by microarray immunoassay reveals the diversity of immune response to the peanut allergen, Ara h 2. *J Allergy Clin Immunol.* 2005, *116*, 893-899.
- [30] Stanley, J. S., King, N., Burks, A. W., Huang, S. K., *et al.*, Identification and mutational analysis of the immunodominant IgE binding epitopes of the major peanut allergen Ara h 2. *Arch Biochem Biophys.* 1997, *342*, 244-253.
- [31] Reese, G., Ballmer-Weber, B. K., Wangorsch, A., Randow, S., Vieths, S., Allergenicity and antigenicity of wild-type and mutant, monomeric, and dimeric carrot major allergen Dau c 1: destruction of conformation, not oligomerization, is the roadmap to save allergen vaccines. *J Allergy Clin Immunol.* 2007, *119*, 944-951.
- [32] Clement, G., Boquet, D., Mondoulet, L., Lamourette, P., *et al.*, Expression in *Escherichia coli* and disulfide bridge mapping of PSC33, an allergenic 2S albumin from peanut. *Protein Expr.Purif.* 2005, *44*, 110-120.
- [33] Caruelle, D., Grassi, J., Courty, J., Groux-Muscattelli, B., *et al.*, Development and testing of radio and enzyme immunoassays for acidic fibroblast growth factor (aFGF). *Anal Biochem* 1988, *173*, 328-339.
- [34] Gasteiger, E., Hoogland, C., Gattiker, A., Duvaud, S., *et al.*, in: Walker, J. M. (Ed.), *The Proteomics Protocols Handbook*, Humana Press 2005.
- [35] Bernard, H., Drumare, M. F., Guillon, B., Paty, E., *et al.*, Immunochemical characterisation of structure and allergenicity of peanut 2S albumins using different formats of immunoassays. *Anal.Bioanal.Chem.* 2009, *395*, 139-146.

- [36] Takai, T., Yokota, T., Yasue, M., Nishiyama, C., *et al.*, Engineering of the major house dust mite allergen Der f 2 for allergen-specific immunotherapy. *Nat Biotechnol* 1997, 15, 754-758.
- [37] Toda, M., Reese, G., Gadermaier, G., Schulten, V., *et al.*, Protein unfolding strongly modulates the allergenicity and immunogenicity of Pru p 3, the major peach allergen. *J Allergy Clin Immunol* 2011.
- [38] Orlandi, A., Grasso, F., Corinti, S., Marinaro, M., *et al.*, The recombinant major allergen of *Parietaria judaica* and its hypoallergenic variant: in vivo evaluation in a murine model of allergic sensitization. *Clin Exp Allergy* 2004, 34, 470-477.
- [39] Mueller, G. A., Gosavi, R. A., Pomés, A., Wünschmann, S., *et al.*, Ara h 2: crystal structure and IgE binding distinguish two subpopulations of peanut allergic patients by epitope diversity. *Allergy* 2011, 66, 878-885.

Table 1

Table 1. Serological and clinical data of the peanut-allergic patients

Patient #	Age (year)	Sex	Clinical signs (medical history)	Open OFC Threshold (mg)	Ara h 6-specific IgE (IU/mL)
51	5	M	V, GU	400	700
470	4	M	A, R, U	6,000	800
263	10	F	A, V, CP	800	440
134	1.5	M	QO, GU, V	ND	150
110	8	M	A, U, V	200	46
39	6	M	A, R, U	50	160
102	11	M	QO, GU, V	ND	170
430	4	M	R	400	25
443	12.5	M	A, RC, V	1,600	100
496	5.5	M	A, GU	1,600	87

M, Male; F, Female; A, Asthma; CP, Cutaneous Pruritus; GU, Generalized Urticaria; QO, Quincke's Oedema; R, Rhinitis; RC, Rhino Conjunctivitis; U, Urticaria; V, Vomiting; OFC, Oral Food Challenge (threshold dose eliciting reactions); ND, not done (risk of anaphylactic shock).

Table 2

Table 2. Strategy used for the disruption of disulfide bridges in Ara h 6

Constructs	Removed disulfide bridges	Mutagenic primers (Sequences [5'→3'])
H6-5	C84A + C124A	C84A → CATGGAAAACCAG <u>GCC</u> GACCGTCTGCAGGACCG C124A → CGTTTCTGGTGGTCGT <u>GCC</u> TAATAGGATCCGGCTGC
H6-5.1	C84A C14A + + C124A C71A	C14A → GGTGACTCTTCTT <u>GCC</u> GAAACGTCAGGTTGACC C71A → GGAAAACACTGAAACG <u>GCC</u> ATGTGCGAAGCTCTGC
H6-5.2	C84A C26A + + C124A C58A	C26A → GTTAACCTGAAACCG <u>GCC</u> GAAACAGCACATCATGC C58A → GACCAGCAGCAGCGT <u>GCC</u> TGCGACGAACTGGACC
H6-5.3	C84A C59A + + C124A C107A	C59A → CAGCAGCAGCGTTG <u>GCC</u> GACGAACTGGACCAGATGG C107A → GAACCTGCCGCAGCAG <u>GCC</u> AACTCCGTGCTCCG
H6-5.4	C84A C73A + + C124A C115A	C73A → CACTGAACGCTGCATG <u>GCC</u> GAAAGCTCTGCAGCAG C115A → CGTGCTCCGCAGCGT <u>GCC</u> GACCTGGACGTTTCTGG
H6-5.1.4	C84A C14A C73A + + + C124A C71A C115A	C71A+C73A → GAAAACACTGAAACG <u>GCC</u> ATG <u>GCC</u> GAAAGCTCTGCAGCAG
H6-5.2.3	C84A C26A C59A + + + C124A C58A C107A	C58A+C59A → GACCAGCAGCAGCGT <u>GCCGCC</u> GACGAACTGGACCAGATGG

Substitutions of Cys by Ala residue are indicated by the codon GCC bolded and underlined.

Table 3

Table 3: Identification by MS of the heterodimeric structures observed after trypsin digestion

Constructs (mass, Da)	Masses observed after trypsinolysis		
	<i>under non-reducing conditions</i>	under reducing conditions f(assigned peptide sequence)	
		small subunit	large subunit
rAra h 6	13,787 13,554 ^a	4,986 f(G ₆ -R ₄₇) 4,759 f(Q ₈ -R ₄₇)	8,800 f(S ₅₁ -C ₁₂₄)
H6-5	13,479	4,986 f(G ₆ -R ₄₇) 4,755 f(Q ₈ -R ₄₇)	8,736 f(S ₅₁ -A ₁₂₄)
H6-5.1	12,559 12,021	3,824 f(Q ₁₇ -R ₄₇) 3,325 f(V ₂₁ -R ₄₇)	8,700 f(S ₅₁ -A ₁₂₄)
H6-5.2	7,306 ^a 6,852 ^a		3,418 f(A ₅₈ -R ₈₆) 3,932 f(A ₅₈ -R ₉₀)
H6-5.3	7,412 ^a 6,965 ^a		3,418 f(C ₅₈ -R ₈₆) 3,929 f(C ₅₈ -R ₉₀)
H6-5.4	12,493	4,758 f(Q ₈ -R ₄₇)	7,733 f(S ₅₁ -R ₁₁₄)

^a products corresponding to heteropolymeric structures

Supplemental Table S1

Table S1. Serological and clinical data of the 40 peanut-allergic patients whose immunopurified IgE antibodies were used for the mediator release assay

Patient #	Age (year)	Sex	Clinical signs	Whole Peanut Protein-specific IgE (IU/mL)
39	6	M	A, R, U	190
42	4	M	AO	500
44	12	M	AP, QO	250
51	5	M	V, GU	1000
60	5.5	F	RC, AP	6
70	10	M	QO, V, RC	130
72	6	F	A, GU	23
87	8	M	C, V	450
93	2,5	M	GU	7
102	11	M	QO, GU, V	310
109	8	F	A	450
110	8	M	A, U, V	60
127	3	F	V, AP	25
134	1.5	M	QO, GU, V	180
137	3	M	R, GU	5
148	4	M	A, R	38,69
185	5	M	C, AO	1
186	4.5	M	A, R, U	92
190	4	M	RC, AP	204
198	4	M	V, CP	82
203	5	F	A, R, U	22
205	9	F	V, CP	7
250	11	F	U, V	254
263	10	F	A, V, CP	500
315	13	F	QO, V, GU	190
330	12	M	QO, V, GU	12
375	4	M	U, C	7
388	15.5	F	OS, LO	229
393	3	M	U	11
403	4	F	C, U	20
430	4	M	R	52
439	7	F	QO, V, GU	80
443	12.5	M	A, RC, V	240
457	6	F	V, AP	24
470	4	M	A, R, U	1300
482	6	M	U	4
496	5.5	M	A, GU	126
644	5	M	U, V	3
655	8	M	U	60
658	11	F	A, AP	20

M, Male; F, Female; A, Asthma; AO, Angio Oedema, AP, Abdominal Pain; C, Conjunctivitis; CP, Cutaneous Pruritus; GU, Generalized Urticaria; LO, Laryngeal Oedema; OS, Oral Syndrome; QO, Quincke's Oedema; R, Rhinitis; RC, Rhino Conjunctivitis; U, Urticaria; V, Vomiting.

Figures legends

Figure 1. Alignment of Ara h 2 and Ara h 6 and schematic representation of the disulfide bond pattern conserved in 2S-albumins. Dotted line indicates the additional disulfide bridge, DB5, in Ara h 6 compared to Ara h 2. Arrows point to tryptic cleavage sites. Grey arrow indicates the cleavage site processed *in vivo* by peanut protease for Ara h 6 [16, 20] or *in vitro* by trypsin for Ara h 2 or Ara h 6, thus leading to the “typical” pattern of processed 2S-albumins with two small and large subunits [21]. Linear IgE-binding epitopes in Ara h 2 are grey-shaded [26, 30, 39]. The five α -helices are represented by dashed lines. Numbering of Ara h 6 residues is indicated.

Figure 2. Resistance of Ara h 6 variants to digestion by trypsin. Intact and digested protein samples were separated by SDS-PAGE under reducing conditions.

Figure 3. Far UV circular dichroism spectra of the different Ara h 6 variants and the denatured allergen (H6_{red}).

Figure 4. Competitive binding-inhibition (EAST inhibition) of IgE antibodies from patient #443 to Ara h 6 by recombinant Ara h 6 variants and the denatured allergen (H6_{red}), before (A) and after (B) trypsin digestion.

Figure 5. Competitive binding-inhibition (EAST inhibition) of IgE antibodies from ten peanut-allergic patients to Ara h 6 by recombinant Ara h 6 variants and the denatured allergen (H6_{red}), before (A) and after (B) trypsin digestion. 50% inhibitory concentration (IC₅₀) were determined. NC, not calculable.

Figure 6. Mediator release assay with RBL SX-38 cells passively sensitized with immunopurified human IgE antibodies from a pool of 40 peanut-allergic patients (supplemental Table S1) in response to increasing concentrations of recombinant Ara h 6 variants and the denatured allergen (H6_{red}), before (A) and after (B) trypsin digestion.

Figure 1.




Figure 2.




Figure 3.




Figure 5.




Figure 6.

